LIFECODES^® Donor Specific Antibody Assay

Detect donor-specific HLA antibodies against Class I and/or Class II antigens.

Resource Library Learn

Detect donor-specific HLA antibodies against Class I and/or Class II antigens.

The DSA assay makes it possible to screen for the presence of antibodies directed against the HLA antigens of the donor. It is ideal for pre- and post-transplant testing.

Detect donor specific HLA IgG antibodies against Class I and/or Class II antigens in a single well
Freeze donor lysate for future testing
No cell viability issues
Run from 1 to 91 assays at a time

Research Use Only (RUO). Not for use in diagnostic procedures.

DSA Brochure

Luminex LX200 Support Reassurance Letter

HLA Antibody Identification

Resource Library

PACKAGE INSERTS (PI/ IFU), SAFETY DATA SHEETS (SDS), CERTIFICATES of ANALYSIS, LOT SPECIFIC FILES, and more can be accessed on our customer center.

Our Certifications

View All Certifications

Related Products

Testimonial
Transplant
Customer

Overall, Nanopore sequencing is an excellent option for the future of HLA typing methodology.

Dr. Ana M Lazaro-Shiben, PhD, CHS, Immunogenetics Laboratory Johns Hopkins University School of Medicine

Let's Get Started On Your Story

Testimonial
Transplant
Customer

“We were astonished by the potential impact of this solution to enable sensitized patients to benefit from reliable epitopebased matching of deceased donors for the first time.”

Prof. Jean-Luc Taupin, PharmD, PhD, President of the Francophone Society of Histocompatibility and Immunogenetics, Immunology and Histocompatibility Laboratory, Saint-Louis Hospital

Let's Get Started On Your Story

Testimonial
Transplant
Customer

The technology is cost effective, scalable for the parallel typing of one-to-many samples, in a short period of time, providing excellent opportunities for the typing of deceased donors, elevating our matching capabilities to allow for epitope matching of these donors.

Prof. Dimitri S. Monos, PhD, Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania

Let's Get Started On Your Story

Testimonial
Transplant
Customer

I really appreciate Immucor's continuous interest in listening to the customer. That is what makes Immucor a great partner to our labs. I know that our needs and ideas will be heard and taken into consideration to improve the products. That makes a world of difference to us in the labs and is truly appreciated.

Valia Bravo-Egana, PhD, F(ACHI), MBA, Director, Technical Supervisor and Clinical Consultant, Histocompatibility/Immunology Laboratory, Medical College of Georgia

Let's Get Started On Your Story

Testimonial
Transplant
Customer

Immucor products enable us to accurately assign HLA antibody specificities for better transplant outcomes!

Sam Ho, PhD, D(ABHI), FAACC, HLA Lab Director, Gift of Hope Organ & Tissue Donor Network

Let's Get Started On Your Story

Testimonial
Transplant
Customer

The fact that Immucor representatives are former transplant technologists adds one more layer of support for us. I appreciate Immucor's commitment to comprehensive customer support, from assay and software development to technical and educational support. It's a team approach between vendor and customer that is more than a business relationship. It's a joint mission to benefit patients.

Ellen Klohe, PhD, D(ABHI), HLA Laboratory Director, Vitalant Spokane Laboratory

Let's Get Started On Your Story

Upcoming Events,
Webinars & Workshops

View Events Calendar

Upcoming Event

BBTS 2025

When

October 14th 2025

Where

United Kingdom

View

Upcoming Event

EEMEA Scientific Seminar 1st Werfen EEMEA Transfusion Seminar

When

October 16th 2025

Where

Radisson Blu Hotel Lithuania

View

Upcoming Event

Blood 2025 & ISBT Perth 2025

When

October 26th 2025

Where

Perth, Australia

View

Keep Up With Us

View All News & Blogs

News & Blogs

Werfen acquires Omixon

Werfen has completed the acquisition of Omixon, a privately held company based in Budapest, Hungary, focused on the development and commercialization of Next Generation Sequencing (NGS) technologies in transplant diagnostics. The acquisition expands Werfen’s portfolio of transplant diagnostics solutions for...

Continue Reading View All